Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Decera Clinical Education Oncology Podcast · Jul 28, 2025 · 39m

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts:

POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL

ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL

CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL

InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL

SHR2554: Oral EZH2 Inhibitor in R/R PTCL

SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters…